Table 1 Baseline characteristics according to stratum and analysis cohort.
No risedronate (primary analysis cohort) | Risedronate (secondary analysis cohort) | |||||
|---|---|---|---|---|---|---|
Stratum I (N = 404) | Stratum II (N = 105) | P value | Stratum II (N = 108) | Stratum III (N = 80) | P value | |
Age, median (IQR) | 58.6 (54.8–62.2) | 60.1 (57.2–64.1) | <0.001 | 59.7 (55.3–64.8) | 61.6 (57.2–64.3) | 0.15 |
BMI (kg/m2), median (IQR) | 28.5 (25.4–32.6) | 26.2 (23.8–30.1) | 0.003 | 25.8 (23.7–29.3) | 25.6 (23.4–28.3) | 0.61 |
Previous HRT use (%) | 200 (48.7%) | 54 (46.2%) | 0.63 | 57 (52.8%) | 35 (43.8%) | 0.22 |
Never smokers (%) | 227 (55.2%) | 74 (63.3%) | 0.31 | 64 (59.3%) | 49 (61.3%) | 0.38 |
Hysterectomy (%) | 135 (32.9%) | 38 (32.5%) | 0.94 | 29 (26.9%) | 25 (31.3%) | 0.51 |
Oophorectomy (%) | 59 (14.4%) | 16 (13.7%) | 0.85 | 20 (18.5%) | 6 (7.5%) | 0.03 |
Lowest T-score, median (IQR) | −0.37 (−0.87 to 0.22) | −1.52 (−1.94 to −1.20) | <0.001 | −1.63 (−2.02 to −1.23) | −2.75 (−3.0 to −2.5) | <0.001 |
